Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAP immunosuppressive CAR-DC
- Development stage
- Phase 1
- Lead developer
- Zhejiang University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
FAP immunosuppressive CAR-DC (iCDC) is an experimental cell therapy being developed by the Second Affiliated Hospital, School of Medicine, Zhejiang University. It consists of dendritic cells engineered to express a chimeric antigen receptor (CAR) targeting Fibroblast Activation Protein (FAP). This therapy is specifically designed for the treatment of end-stage dilated cardiomyopathy (DCM). Unlike traditional CAR-T cell therapies that are typically designed for cytotoxic depletion of target cells, this 'immunosuppressive' CAR-DC approach aims to modulate the immune environment and target FAP-expressing cardiac fibroblasts, which are primary drivers of pathological fibrosis and cardiac remodeling in heart failure. By targeting these cells, the therapy seeks to reduce fibrosis and improve cardiac function in patients with end-stage disease.
- Other names
- FAP-targeted immunosuppressive chimeric antigen receptor-dendritic cellFAP immunosuppressive CAR-DC
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on FAP immunosuppressive CAR-DC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAP immunosuppressive CAR-DC.